In addition, FDA provided clearness on the advancement requirements to join up ARX-02 for the broader indication of chronic breakthrough pain in opioid-tolerant patients, where we believe that ARX-02 can impact on the entire lives of a broader array of opioid-tolerant patients.’.. AcelRx completes ARX-02 End-of-Phase 2 ending up in FDA for tumor breakthrough pain management system AcelRx Pharmaceuticals, Inc.In the statistical analyses of antibody titers, the titers had been logarithmically converted to allow the evaluation of geometric mean titers. SAS software, version 9.1 , was used for statistical analysis. Results Study Participants A total of 14,445 children, 6 to 71 months of age, were evaluated for inclusion in the analysis. Of these, 2445 children were excluded: 1732 children were ineligible, and 713 acquired parents who declined to have them participate. We assigned 12 randomly, 000 participants in a ratio of 1 1:1 to receive the placebo or vaccine; these individuals composed the data established for the intention-to-deal with analysis .